A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 3, 2017

Primary Completion Date

September 13, 2023

Study Completion Date

March 3, 2035

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

Patient-derived CD19- and CD22 specific CAR

Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt

Trial Locations (5)

20010

Children's National Medical Center, Washington D.C.

46202

Riley Hospital for Children, Indianapolis

90027

Children's Hospital Los Angeles, Los Angeles

98105

Seattle Children's Hospital, Seattle

V6H 3V4

Children's and Women's Health Centre of British Columbia, Vancouver

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER